Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer

Plasma cell-free tumor DNA, or circulating tumor DNA (ctDNA), from liquid biopsy is a potential source of tumor genetic material, in the absence of tissue biopsy, for EGFR testing. Our validation study reiterates the clinical utility of ctDNA next generation sequencing (NGS) for EGFR mutation testin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lung Cancer (Auckl)
Autors principals: Veldore, Vidya H, Choughule, Anuradha, Routhu, Tejaswi, Mandloi, Nitin, Noronha, Vanita, Joshi, Amit, Dutt, Amit, Gupta, Ravi, Vedam, Ramprasad, Prabhash, Kumar
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2018
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5757203/
https://ncbi.nlm.nih.gov/pubmed/29379323
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/LCTT.S147841
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars